Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • May 27, 2010

166_ip_2010-05-27_242b7870-f526-426b-ae9f-81a3601ee717.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Morgan Stanley European MedTech & Services Conference

May 27, 2010

Safe Harbor Statement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Achieving Profitable Growth in Attractive Health Care Segments

Fresenius Medical Care is fully consolidated in the financial statements of Fresenius SE

Fresenius Group: Financial Results

S
l
a
e
s		 E
B
I
T		 *
N
i
t
e
n
c
o
m
e
/
Q
1
1
0		 €
3
6
4
3
m
,		 €
5
0
0
m		 €
1
1
9
m
G
h
t
t
t
t
r
o
a
c
o
n
s
a
n
w
t
c
r
r
e
n
c
r
a
e
s
u
y		 %
1
0		 %
7		 8
%
G
h
l
t
t
t
r
o
w
a
a
c
u
a
t
c
u
r
r
e
n
c
y
r
a
e
s		 %
8		 %
5		 %
8

Net income attributable to Fresenius SE and before special items due to MEB and CVR accounting

Fresenius Group: Financial Results by Business Segment

/
Q
0
1
1		 F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 F
i
r
e
s
e
n
u
s
K
b
i
a		 F
i
r
e
s
e
n
u
s
H
l
i
e
o
s		 F
i
r
e
s
e
n
u
s
V
d
a
m
e
S
l
a
e
s
G
h
t
r
o
w		 \$
S
U
2
8
8
2
m
,
%
1
3		 €
8
0
0
m
%
1
1		 €
6
0
8
m
%
5		 €
1
5
6
m
%
3
4
E
B
I
T
G
h
t
r
o
w		 \$
U
S
2
3
4
m
%
7		 €
1
4
5
m
%
5		 €
5
2
m
8
%
1		 €
7
m
%
7
5

Fresenius Kabi: Update Q1/10

    • Strong start into the year, organic sales growth at 9%
  • -12% organic growth in clinical nutrition
  • -11% organic growth in IV drugs
  • EBIT margin of 18.1% fully in line with expectations
  • No significant impact from US healthcare reform and current German reform plans expected
  • APP Pharmaceuticals update:
  • 14% sales growth in non-heparin portfolio
  • 1 product approval, 2 ANDA filings YTD, 34 ANDAs pending

Fresenius Helios: Update Q1/10

  • -Continued strong organic sales growth of 6%
    • Improved key performance indicators
    • More than 152,000 in-patient hospital admissions in Q1, 4% organic growth
    • Average length of hospital stay at all-time low of 6.9 days
  • -Fully on track to achieve 2010 guidance
  • Excellent progress at Krefeld hospital reconstruction on plan – radiation clinic in operation
    • Privatization activity expected to gain momentum in 2010/2011

Fresenius Vamed: Update Q1/10

    • Excellent 34% sales growth, driven by Ukraine medical equipment contract
    • Order entry nearly tripled to €260 million
    • €102 million turnkey contract for extension of a 500-bed hospital in Lower Austria
    • Order backlog (€838 million) at all-time high – double the size of '09 project sales
    • Regional distribution: 71% Europe (PIIGS: 0%) 29% RoW

Fresenius Group: 2010 Financial Outlook Fully Confirmed

F
i
r
e
s
e
n
u
s
M
d
i
l
C
e
c
a
a
r
e		 S
l
a
e
s
N
I
t
e
n
c
o
m
e		 \$
U
S
1
2
b
n
>
\$
U
S
8
9
5
0
9
0
m
–
F
i
r
e
s
e
n
u
s
K
b
i
a		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T
i
m
a
r
g
n		 7
9
%
i
o
r
g
a
n
c
–
8
9
%
1
1
–
i
F
r
e
s
e
n
u
s
H
l
i
e
o
s		 S
l
h
t
a
e
s
g
r
o
w
E
B
I
T		 %
i
3
5
o
r
g
a
n
c
–
€
2
2
0
2
3
0
m
–
F
i
r
e
s
e
n
s
u
d
V
a
m
e		 S
l
h
t
a
e
s
g
r
o
w
h
E
B
I
T
t
g
r
o
w		 0
%
5
1
–
%
5
1
0
–
i
F
r
e
s
e
n
u
s
B
i
h
t
o
e
c		 E
B
I
T		 €
3
5
4
0
m
-
–
-

Fresenius Group: 2010 Financial Outlook Fully Confirmed

h
R
t
e
e
n
e
g
r
o
v
u
w
t
t
t
a
c
o
n
s
a
n
c
r
r
e
n
c
u
y		 %
7
9
–
*
i
h
N
t
t
e
n
c
o
m
e
g
r
o
w
t
t
t
a
c
o
n
s
a
n
c
u
r
r
e
n
c
y		 8
%
1
0
–
C
a
p
e
x		 5
%
f
G
l
o
r
o
u
p
s
a
e
s
~

* Net income attributable to Fresenius SE and before special items due to MEB and CVR accounting

Attachments

Fresenius Group: Profit and Loss Statement

€
m		 /
Q
0
1
1		 /
Q
0
9
1		 G
h
Y
Y
t
r
o
w
o
l
t
a
c
u
a
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s
S
l
a
e
s		 3
6
4
3
,		 3
3
7
3
,		 8
%		 1
0
%
E
B
I
T		 5
0
0		 4
7
7		 %
5		 %
7
N
i
t
t
t
e
n
e
r
e
s		 1
4
3
-		 1
4
5
-		 1
%		 2
%
-
I
t
n
c
o
m
e
a
e
s
x		 1
1
9
-		 1
0
7
-		 %
1
1
-		 %
1
5
-
*
N
i
t
e
n
c
o
m
e		 9
1
1		 0
1
1		 8
%		 8
%

* Net income attributable to Fresenius SE and before special items due to MEB and CVR accounting

Fresenius Group: Cash Flow

€
m		 /
Q
1
1
0		 L
T
M
i
M
a
r
g
n		 *
/
Q
1
0
9		 L
T
M
i
M
a
r
g
n		 G
h
t
r
o
w
Y
Y
o
O
i
C
h
l
t
F
p
e
r
a
n
g
a
s
o
w		 4
3
8		 %
1
2
5		 1
8
2		 %
7
6		 %
1
4
1
C
(
)
t
a
p
e
x
n
e		 3
0
1
-		 %
4
5		 1
4
7
-		 %
5
6		 2
%
1
F
C
h
F
l
r
e
e
a
s
o
w
(
)
b
d
d
d
d
f
i
i
i
i
i
t
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 3
0
8		 8
1
%		 3
5		 2
0
%		 --
i
i
i
A
t
(
)
t
c
q
u
s
o
n
s
n
e		 6
6
-		 8
6
-		 %
2
3
D
i
i
d
d
e
n
s
v		 2
4
-		 1
1
-		 %
1
1
8
-
F
C
h
F
l
r
e
e
a
s
o
w
(
)
f
i
i
i
d
d
i
i
d
d
t
t
a
e
r
a
c
q
s
o
n
s
a
n
e
n
s
u
v		 2
1
8		 4
6
%		 6
2
-		 2
2
3
%
-		 --

* After FMC restatement of noncontrolling interest

Cash Flow Development LTM

€
m		 O
p
e
r
a		 i
C
F
t
n
g		 C
a
p
e		 (
)
t
n
e
x		 *
C
h
l
F
F
r
e
e
a
s
o
w
/
L
T
M
Q
0
1
1		 L
T
M
M
i
a
r
g
n		 /
L
T
M
Q
0
1
1		 L
T
M
M
i
a
r
g
n		 /
L
T
M
Q
0
1
1		 L
T
M
M
i
a
r
g
n
4
3
1		 1
3
6
%		 (
)
1
2
0		 (
)
3
8
%		 3
1
1		 9
8
%
2
4
9		 %
1
0
2		 (
)
1
2
3		 (
)
%
5
0		 1
2
6		 %
5
1
7
8		 1
1
9
%		 (
)
5		 (
)
0
8
%		 7
3		 1
1
1
%
Co
/
te
rp
or
a
O
he
t
r		 4
2
-		 /
n
a		 (
)
8		 /
n
a		 5
0
-		 /
n
a
l.
C
F
M
ex
c		 7
1
6		 1
1
5
%		 (
)
2
5
6		 (
)
4
1
%		 4
6
0		 7
4
%

Margin = in % of sales

* Before Acquisitions and Dividends

Fresenius Group: Debt and Interest Ratios

M
3
1
a
r
,
2
0
1
0		 D
3
1
e
c
,
2
0
0
9
(
)
D
b
€
t
e
m
\$
he
f
5
6
%
U
S
t
re
o
de
in
d
te
no
m
a		 8
5
0
0
,		 8
2
9
9
,
(
)
d
b
N
€
t
t
e
e
m		 8
0
3
3
,		 7
8
7
9
,
d
b
/
N
E
B
I
T
D
A
t
t
e
e		 3
0		 3
0
/
E
B
I
T
D
A
I
t
t
n
e
r
e
s		 4
5		 4
5

Net debt/EBITDA

YE/01 YE/02 YE/03 YE/04 YE/05 YE/06 YE/07 YE/08 YE/09 Q1/10

Debt excludes Mandatory Exchangeable Bonds

Fresenius Kabi: Strong Organic Sales Growth

€
m		 /
Q
1
1
0		 /
Q
1
0
9		 O
i
r
g
a
n
c
G
h
t
r
o
w
I
f
i
T
h
n
u
s
o
n
e
r
a
p
y		 1
9
6		 1
6
8		 %
6
I
V
D
r
u
g
s		 2
5
5		 2
3
7		 %
1
1
C
l
i
i
l
i
i
N
t
t
n
c
a
r
o
n
u		 2
4
5		 2
1
6		 %
1
2
/
M
d
i
l
D
i
e
c
a
e
v
c
e
s
T
f
i
T
h
l
r
a
n
s
s
o
n
e
c
n
o
o
g
u
y		 1
0
4		 1
0
1		 %
1
T
l
l
t
o
a
s
a
e
s		 8
0
0		 2
2
7		 9
%

Fresenius Kabi: Strong Organic Sales Growth

€
m		 Q
/
1
1
0		 Q
/
1
0
9		 O
i
r
g
a
n
c
G
h
t
r
o
w
E
u
r
o
p
e		 4
0
9		 3
7
6		 6
%
N
h
A
i
t
o
r
m
e
r
c
a		 9
1
7		 8
1
6		 %
1
1
i
i
f
i
A
P
s
a
a
c
c
-		 1
2
8		 1
1
1		 %
1
4
/
L
i
A
i
A
f
i
t
a
n
m
e
r
c
a
r
c
a		 8
4		 6
7		 %
7
T
l
l
t
o
a
s
a
e
s		 8
0
0		 7
2
2		 %
9

Fresenius Kabi: EBIT Growth Fully in Line with Expectations

€
m		 /
Q
1
1
0		 /
Q
1
0
9		 G
h
t
r
o
w
E
u
r
o
p
e
M
i
a
r
g
n		 8
6
2
0
%
1.		 8
0
2
3
%
1.		 %
8
N
h
A
i
t
o
r
m
e
r
c
a
M
i
a
r
g
n		 4
7
2
3
%
6.		 5
0
2
9.
8
%		 6
%
-
/
/
A
i
P
i
f
i
L
i
A
i
A
f
i
t
s
a
a
c
c
a
n
m
e
r
c
a
r
c
a
-
i
M
a
r
g
n		 3
5
%
1
6.
5		 2
7
%
1
5.
2		 3
0
%
C
d
C
R
D
t
t
&
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 2
3
-		 1
9
-		 %
2
1
-
l
T
E
B
I
T
t
o
a		 1
4
5		 1
3
8		 %
5
M
i
a
r
g
n		 8
%
1
1		 9
%
1
1

Fresenius Helios: Excellent Sales and EBIT Growth

€
m		 /
Q
1
1
0		 /
Q
1
0
9		 G
h
t
r
o
w
l
l
T
t
o
a
s
a
e
s		 8
6
0		 5
7
7		 %
5
E
B
I
T
E
b
l
i
h
d
l
i
i
f
l
i
t
t
s
a
s
e
c
n
c
p
o
r
o
o
M
i
a
r
g
n		 2
5
%
8.
6		 *
3
4
%
7.
5		 2
%
1
/
A
i
i
i
D
i
i
t
t
t
c
q
s
o
n
s
e
s
r
e
s
u
v
u
(
/
)
l
i
d
i
d
l
i
d
i
1
t
t
c
o
n
s
o
a
o
n
e
c
o
n
s
o
a
o
n
r
<
y		 0 *
1
l
T
E
B
I
T
t
o
a		 5
2		 4
4		 1
8
%
M
i
a
r
g
n		 %
8
6		 %
7.
6

* Prior year EBIT split adjusted to current portfolio

Fresenius Helios: Performance Indicators

Q
/
1
1
0		 Q
/
1
0
9		 C
h
a
n
g
e
*
N
f
h
i
l
t
o
o
o
s
p
a
s
A
l
i
i
t
c
u
e
c
n
c
s
-
l
i
i
P
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 6
1
2
4
1
9		 6
2
3
4
1
9		 %
2
-
-2
%
%
0
*
N
f
b
d
o
o
e
s
l
i
i
A
t
c
u
e
c
n
c
s
-
P
l
i
i
t-
t
o
s
a
c
u
e
c
a
r
e
c
n
c
s
-		 8
1
5
1
6
,
1
5,
0
4
9
3,
4
6
7		 8
8
3
1
5
,
1
5,
1
1
6
3,
4
6
7		 0
%
%
0
0
%
**
d
i
i
A
m
s
s
o
n
s
(
)
A
i
i
t
t
t
c
e
c
a
r
e
n-
p
a
e
n
u
-		 1
5
2,
7
3
0		 1
4
7,
6
2
3		 3
%
**
O
c
c
u
p
a
n
c
y
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 8
0
%		 9
%
7
**
(
)
A
l
h
f
d
t
t
v
e
r
a
g
e
e
n
g
o
s
a
y
a
y
s
A
t
c
u
e
c
a
r
e
-
P
t-
t
o
s
a
c
u
e
c
a
r
e
-		 6.
9
3
0.
1		 7.
0
3
0.
5

Dec 31, 2009

**Clinics in Germany

Fresenius Vamed: Excellent Sales and EBIT Growth

€
m		 /
Q
1
1
0		 /
Q
1
0
9		 G
h
t
r
o
w
P
j
b
i
t
r
o
e
c
s
n
e
s
s
u
S
i
b
i
e
r
v
c
e
u
s
n
e
s
s		 1
0
2
5
4		 6
8
8
4		 5
0
%
%
1
3
T
l
l
t
o
a
s
a
e
s		 1
5
6		 1
1
6		 %
3
4
T
l
E
B
I
T
t
o
a
i
M
a
r
g
n		 7
4
5
%		 4
3.
4
%		 %
7
5

O
d
i
k
t
r
e
r
n
a
e

O
d
b
k
l
r
e
r
a
c
o
g		 2
0
6
8
3
8		 8
8
**
9
6
7		 9
%
1
5
2
3
%

* Project business only

** Dec 31, 2009

Financial Calendar

8
0
3
0
2
0
1
0		 t
R
h
l
f
t
1
s
2
0
1
0
e
p
o
r
o
n
a
0
2
1
1
2
0
1
0		 d
t-
R
t
1
s
3
r
t
2
0
1
0
e
p
o
r
o
n
q
u
a
r
e
r
s

Contact

Birgit Grund SVP Investor Relations Fresenius SE

Telephone: +49 6172 608-2485 e-mail: [email protected]

For further information and current news: http://www.fresenius.com

Subject to the prior approval by the Annual General Meeting.

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.